Dechra Pharmaceuticals (Dechra Pharmaceuticals) Net Income From Continuing Operations : $6.0 Mil (TTM As of Jun. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Dechra Pharmaceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Dechra Pharmaceuticals's net income from continuing operations for the six months ended in Jun. 2023 was $-48.4 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2023 was $6.0 Mil.

Dechra Pharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for Dechra Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dechra Pharmaceuticals Net Income From Continuing Operations Chart

Dechra Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Net Income From Continuing Operations

Get a 7-Day Free Trial

49.43

65.33

117.81

117.61

7.96

Dechra Pharmaceuticals Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Net Income From Continuing Operations	Get a 7-Day Free Trial															61.29	76.33	46.92	54.32	-48.36

Dechra Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $6.0 Mil.

Dechra Pharmaceuticals (Dechra Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dechra Pharmaceuticals PLC (OTCPK:DCHPF) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

DPHAY:USA DPHl:UK DPH:UK 1PK:Germany

Address

24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, GBR, CW9 7UA

Website

https://www.dechra.com

Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.

Dechra Pharmaceuticals (Dechra Pharmaceuticals) Headlines

From GuruFocus

Ron Baron Comments on Dechra Pharmaceuticals PLC

By Holly LaFon Holly LaFon • 01-24-2019

Ron Baron Comments on Dechra Pharmaceuticals

By Sydnee Gatewood Sydnee Gatewood • 07-29-2020